Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi's novel stem cell-based ...

Sensei Biotherapeutics (SNSE) announced initial results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug, a conditionally active monoclonal antibody targeting VISTA.

Story March 4 - Atara Biotherapeutics: While the biotech navigates the fallout from the FDA’s move to halt trials of its allogeneic T-cell immunotherapy Ebvallo and a CAR-T candidate ...

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported positive results of voting at the ...